New drug targets for HIV.
A significant number of human immunodeficiency virus (HIV) infections have become resistant to antiretroviral treatment, which means that there is a paramount need for novel drug targets to defeat the virus. Until recently, all HIV drugs inhibited HIV replication by mechanisms operating inside infected cells. In contrast, new antiretroviral drugs operate outside infected cells. Their mechanism of action consists in inhibiting entry of the virus into cells, thereby halting the very first step of HIV replication. Examples of this new class of drugs include entry inhibitors, coreceptor antagonists, and fusion inhibitors. In addition to their novel mechanism of action, this new class of drugs also has potential action against drug-resistant HIV strains, causes minimal adverse effects, and may be administered in a simplified, once-daily dosing regimen. New classes of anti-HIV drugs--and new drugs in existing classes--represent the best hope for people infected with HIV, especially those who have exhausted current therapies.
Bean
Pamela
P
Rogers Memorial Hospital, Oconomowoc, WI 53066, USA. PamBean@charter.net
D000818:Animals; D044966:Anti-Retroviral Agents / Q000494:pharmacology*; D017277:Drug Approval; D016503:Drug Delivery Systems / Q000639:trends; D024882:Drug Resistance, Viral / Q000502:physiology; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans
D044966:Anti-Retroviral Agents